Skip to main content
Signal8

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

$BIIBPress releaseNov 16, 2026, 6:00 PM ETRead the release

Eisai and Biogen presented five-year Clarity AD long-term extension data for LEQEMBI (lecanemab) at CTAD 2026, showing benefits of continuous treatment accrue over time in early Alzheimer's disease. Lecanemab reduced the relative risk of progression to the next disease stage by 36% vs. ADNI natural-history data, and reduced progression to moderate or severe AD by 49%. Among low-tau patients treated early, 66% showed no decline on CDR-SB at five years and 62% showed improvement.

Key figures

Drug Name
lecanemab-irmb (LEQEMBI)
Phase Of Trial
Phase 3
Lte participation
95%
Core study enrollment
1795
Aria e first 12 months
13.5%
Low tau no decline cdr sb
66%
Low tau improvement cdr sb
62%
Patients five years continuous
351
Relative risk reduction progression
36%
Relative risk reduction moderate severe
49%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BIIB: New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026 — AI Analysis | Signal8